It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...

COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising stocks. TheFly reported on February 14 that LifeSci Capital was bullish on CMPS, as the firm initiated ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, is establishing its first Centre ...

LONDON & NEW YORK, February 19, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...

Investing.com -- Compass Pathways Plc (NASDAQ:CMPS) stock surged 33.7% on Tuesday following the announcement of highly statistically significant results from its second Phase 3 trial for COMP360, a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were ...

Additionally, Compass Pathways plans to release new clinical data from its ongoing Phase 3 trials, including results from Parts A and B of the COMP005 trial and Part A of the COMP006 trial. The data ...